Back

Effects of sodium glucose co-transporter-2 inhibitor on atrial tachyarrhythmia burden in patients with cardiovascular implantable electronic device

7 April 2024 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: clinical Treatment EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Assistant Professor Teerapat Nantsupawat

Chiang Mai University, Chiang Mai (Thailand)

7 More presentations in this session

Presentation thumbnail
Is thyroid function testing necessary in all cases of new onset atrial fibrillation diagnosed in the emergency department? - a real-life study
Doctor J. Hytting (Norrkoping, SE)
Abstract Slides Video
Presentation thumbnail
Comparison between Novel and Conventional Electrocardiographic Markers of Atrial Cardiomyopathy for identification of Persons at Risk for Ischemic Stroke
Professor A. Jadidi (Luzern, CH)
Abstract Slides Video
Presentation thumbnail
Incidence and outcome of periinterventional atrial fibrillation in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention
Mr J. Jost (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Early rhythm control in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III
Doctor B. Corica (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Incidence and predictors of heart failure events following cardiac surgery in patients with atrial fibrillation - insights from the LAAOS-III trial
Doctor L. Xing (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: clinical

The Event

Event poster

EHRA 2024

7 April 2024 12:30 CET
You may be interested in
thumbnail
Congress Presentation
The impact of dapagliflozin on left atrial functions and recurrence in non-diabetic patients in the early post-cryoablation period
thumbnail
Congress Presentation
Impact of sodium-glucose cotransporter-2 (SLGT2) inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac devices.
thumbnail
Congress Presentation
The impact of dapagliflozin on left atrial functions in non-diabetic atrial fibrillation patients in the early post-cryoablation period

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources